Alternative Liquidity Capital has announced an offer to purchase up to 10,000,000 Shares of Sinovac Biotech Ltd. The Company’s shares have been suspended from trading since 2019, so investors have limited opportunities to sell their Shares. This Offer provides a way for investors to get cash for their investment.

Minnetonka, MN January 11, 2024 --(PR.com)-- Alternative Liquidity Index LP has announced an offer to purchase up to 10,000,000 Shares of Sinovac Biotech Ltd (“the Company”), an amount equal to approximately 10.05% of outstanding shares, at a price of $0.03 (3 cents) per share (“Offer”).

The Purchaser is a Delaware Limited Partnership and is not affiliated with the Company. The Offer is being made solely for the Purchaser to establish a passive ownership position in the Shares, and provide a liquidity opportunity for legacy investors. Sinovac shares have not traded on an exchange since being halted on February 22, 2019, so investors may otherwise have limited opportunities to sell their shares.

Shareholders should read the Offer and related material carefully because they contain important information. Shareholders are urged to consult with financial and other professional advisors before making any decisions regarding the Offer. This announcement is intended as a notification that the Offer has been made, and does not constitute an invitation to sell. Any action that any Shareholder may take in relation to the Offer is only able to be taken once they receive a copy of the Offer which contains the applicable terms and conditions.

Shareholders may obtain a free copy of the Offer and Transfer Form without charge by visiting our website at: https://www.alternativeliquidity.net or by calling us at (888) 884-8796. Investors may also contact us at info@alternativeliquidty.net to answer questions about the Offer or to obtain Offer documents.

Contact Information:
Alternative Liquidity Capital
Jacob Mohs
(888) 884-8796
Contact via Email
alternativeliquidity.net

Read the full story here: https://www.pr.com/press-release/903946

Press Release Distributed by PR.com